{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:43:33Z","timestamp":1791996213889,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":448,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jtct.2021.12.014","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T11:58:22Z","timestamp":1640260702000},"page":"169.e1-169.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Risk Factors for Early Cytomegalovirus Reactivation and Impact of Early Cytomegalovirus Reactivation on Clinical Outcomes after T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6528-9296","authenticated-orcid":false,"given":"Jacopo","family":"Mariotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faezeh","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Furst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Magri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0316-9402","authenticated-orcid":false,"given":"Lorenzo","family":"Richiardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Granata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"De Philippis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Maisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9720-4207","authenticated-orcid":false,"given":"Danilo","family":"Faraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Sarina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Giaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Harbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Mannina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Valli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Tordato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6636-8954","authenticated-orcid":false,"given":"Rossana","family":"Mineri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bramanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-8310","authenticated-orcid":false,"given":"Raynier","family":"Devillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6239-7387","authenticated-orcid":false,"given":"Luca","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2021.12.014_bib0001","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1083-8791(03)00287-8","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies","volume":"9","author":"Boeckh","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.014_bib0002","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.1365-2141.2001.02468.x","article-title":"Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose","volume":"112","author":"Dominietto","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.12.014_bib0003","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.014_bib0004","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2021.12.014_bib0005","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.bbmt.2014.02.015","article-title":"Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation","volume":"20","author":"Mariotti","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.014_bib0006","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2003-10-3616","article-title":"The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy","volume":"103","author":"Boeckh","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.014_bib0007","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/cid\/ciu364","article-title":"Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation","volume":"59","author":"Ljungman","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2021.12.014_bib0008","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.014_bib0009","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partial HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O'Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.014_bib0010","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/tid.12365","article-title":"Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis","volume":"17","author":"Crocchiolo","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2021.12.014_bib0011","doi-asserted-by":"crossref","first-page":"e12629","DOI":"10.1111\/tid.12629","article-title":"Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation","volume":"19","author":"Slade","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2021.12.014_bib0012","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.bbmt.2012.07.003","article-title":"Improved early outcomes using a T cell replete graft compared with T-cell depleted haploidentical hematopoietic stem cell transplantation","volume":"18","author":"Ciurea","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.014_bib0013","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","article-title":"Unmanipulated haploidentical bone marrow transplantation and post-transplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning","volume":"19","author":"Raiola","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.014_bib0014","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00277-015-2423-y","article-title":"Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings","volume":"94","author":"Tischer","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2021.12.014_bib0015","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jit475","article-title":"High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation","volume":"209","author":"Shmueli","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jtct.2021.12.014_bib0016","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bbmt.2009.11.011","article-title":"Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome","volume":"16","author":"Kasamon","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.014_bib0017","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41409-017-0016-1","article-title":"Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT","volume":"53","author":"Cesaro","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.014_bib0018","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/bloodadvances.2020001620","article-title":"Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy","volume":"4","author":"Mariotti","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2021.12.014_bib0019","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.bbmt.2018.01.013","article-title":"Selecting the best donor for haploidentical transplant: impact of HLA, killer cell immunoglobulin-like receptor genotyping, and other clinical variables","volume":"24","author":"Solomon","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.014_bib0020","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bbmt.2020.10.001","volume":"27","author":"Takenaka","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2021.12.014_bib0021","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s00277-020-04156-6","article-title":"Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies","volume":"99","author":"Gao","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2021.12.014_bib0022","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.014_bib0023","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.014_bib0024","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.014_bib0025","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.014_bib0026","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.014_bib0027","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.12.014_bib0028","unstructured":"European LeukemiaNet. ELN recommendations. Available at: https:\/\/www.leukemia-net.org\/physicians\/recommendations. Accessed on May 2021."},{"key":"10.1016\/j.jtct.2021.12.014_bib0029","unstructured":"Fryer JF, Heath AB, Anderson R, Minor PD; Collaborative Study Group. Collaborative study to evaluate the proposed 1st WHO international standard for Human Cytomegalovirus (HCMV) for nucleic acid amplification technology (NAT)- based assays. 2010. Available at: http:\/\/apps.who.int\/iris\/handle\/10665\/70521. Accessed on May 2021."},{"key":"10.1016\/j.jtct.2021.12.014_bib0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in","volume":"64","author":"Ljungman","year":"2017","journal-title":"clinical trials. Clin Infect Dis"},{"key":"10.1016\/j.jtct.2021.12.014_bib0031","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.014_bib0032","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non-parametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc."},{"key":"10.1016\/j.jtct.2021.12.014_bib0033","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.jtct.2021.12.014_bib0034","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.bbmt.2015.07.019","volume":"21","author":"Takenaka","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.12.014_bib0035","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood-2010-08-304121","article-title":"Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients","volume":"118","author":"Elmaagacli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.014_bib0036","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.014_bib0037","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.3324\/haematol.2016.149880","article-title":"Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide","volume":"101","author":"Goldsmith","year":"2016","journal-title":"Haematologica"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2021.12.014_bib0038","first-page":"4494","article-title":"High incidence of CMV reactivation after haploidentical donor hematopoietic cell transplantation using high-dose post-transplant cyclophosphamide, and its impact on transplant outcomes","volume":"130","author":"Al Malki","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2021.12.014_bib0039","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1182\/blood-2018-99-119603","article-title":"Cytomegalovirus reactivation in haploidentical blood or marrow transplant (BMT) using post-transplant cyclophosphamide (PTCy) is associated with higher non-relapse-related mortality, despite rarity of disease","volume":"132","author":"Dioverti","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.014_bib0040","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1182\/blood.V124.21.1170.1170","article-title":"CD3\/8 T-cell responses to CMV reactivation in patients undergoing haploidentical transplants: a retrospective analysis","volume":"124","author":"Gooptu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.014_bib0041","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","article-title":"CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia","volume":"122","author":"Green","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.12.014_bib0042","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1128\/JCM.01670-06","article-title":"Epidemiologic analysis of reactivated cytomegalovirus antigenemia in patients with cancer","volume":"45","author":"Han","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jtct.2021.12.014_bib0043","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.12.014_bib0044","doi-asserted-by":"crossref","first-page":"e13666","DOI":"10.1111\/ctr.13666","article-title":"Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: a multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies","volume":"33","author":"Girmenia","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jtct.2021.12.014_bib0045","first-page":"478","article-title":"Feasibility and efficacy of CD45RA+ depleted donor lymphocytes infusion after haploidentical transplantation with post-transplantation cyclophosphamide in patients with hematological malignancies","volume":"27","author":"Catsagna","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2021.12.014_bib0046","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721014470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721014470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:04:01Z","timestamp":1763003041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721014470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S2666636721014470"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.12.014","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk Factors for Early Cytomegalovirus Reactivation and Impact of Early Cytomegalovirus Reactivation on Clinical Outcomes after T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}